You are here

Article Text

Article menu
XML
Obstetrics and gynaecology
Protocol
Incidence of omental metastasis in uterine serous carcinoma: study protocol for a systematic review and meta-analysis
  1. Cui Hu1,2,
  2. Lin-Lin Zhang1,
  3. Yu Cheng1,
  4. Fei-Xue Xue1,
  5. Ya Jia3,
  6. Qin Zhao-Juan3,
  7. Du Yi3,
  8. Zhang Qian-Wen3,
  9. He Yue-Dong3,
  10. Zheng Ai3,
  11. Yu Xu3
  1. 1Department of Obstetrics and Gynaecology, Mianzhu People's Hospital, Mianzhu, China
  2. 2Department of Obstetrics and Gynaecology, Southwest Medical University, Luzhou, Sichuan, China
  3. 3Department of Obstetrics and Gynaecology, Sichuan University West China Second University Hospital, Chengdu, Sichuan, China
  1. Correspondence to Dr Yu Xu; xuyu{at}stu.scu.edu.cn

Abstract

Introduction Uterine serous carcinoma accounts for only about 10% of all endometrial cancers but this subtype is the most common amongst non-endometrioid endometrium cancers and contributes to more than half of recurrence and deaths attributed to endometrial cancers. A more extensive surgical staging and adjuvant therapies for uterine serous carcinoma are recommended by many guidelines. However, guidelines vary on recommendations for the methods that should be used for omentum assessment in uterine serous carcinoma and the previously reported incidence of omental metastasis in uterine serous carcinoma had a wide range because of the heterogeneity among these studies. As far as we know, there are no systematic review and meta-analysis available on this topic. The aim of our proposed study is to statistically synthesise the data examining the incidence of omental metastasis in uterine serous carcinoma.

Methods and analysis Systematic searches of three databases (PubMed, Embase and Web of Science) will be performed using prespecified search strategies. We will include original studies that reported incidence of omental metastasis in uterine serous carcinoma and are published before 30 August 2020. Our different investigators will independently conduct the eligible study selection, assess the quality of included studies and extract the needed data. If appropriate, the relevant data will be pooled through a random-effect or fixed-effect meta-analysis based on the heterogeneity among included studies. We will evaluate the overall quality of evidence using appropriate methods.

Ethics and dissemination This proposed study will be based on published data, and thus, there is no requirement for ethics approval. We aim to publish the results of this study in a peer-reviewed journal with good visibility for the fields of gynaecology and gynecologic oncology.

PROSPERO registration number CRD42020200891.

  • gynaecological oncology
  • gynaecology
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi.org/10.1136/bmjopen-2020-043141

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Supplementary materials

    • Supplementary Data

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Footnotes

    • Correction notice This article has been corrected since it first published. The provenance and peer review statement has been included.

    • Contributors YX and AZ conceived the idea. YX, CH, L-LZ, YC and F-XX drafted the protocol. All remaining authors (YJ, Z-JQ, YD, Q-WZ and Y-DH) critically revised all drafts of the manuscript for intellectual content and agreed and approved the final manuscript. YX is the guarantor of the review.

    • Funding This study received funding through the Major Research and Development Project of Sichuan Provincial Department of Science and Technology, from the science and technology department of Sichuan Province, Project Grant Number: 2019YFS0402.

    • Disclaimer The funders’ and authors’ institutions are not responsible for its content.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.